Pediatrix Medical Group, Inc. (NYSE:MD) Given Average Recommendation of “Hold” by Brokerages

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have been given an average rating of “Hold” by the six research firms that are currently covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $22.50.

MD has been the topic of a number of research analyst reports. Jefferies Financial Group reaffirmed a “buy” rating and set a $27.00 price objective on shares of Pediatrix Medical Group in a research report on Monday, April 20th. Truist Financial boosted their price objective on shares of Pediatrix Medical Group from $21.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, April 13th. UBS Group boosted their price objective on shares of Pediatrix Medical Group from $22.00 to $25.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Mizuho set a $24.00 price objective on shares of Pediatrix Medical Group in a research report on Friday, May 8th. Finally, Deutsche Bank Aktiengesellschaft set a $19.00 price objective on shares of Pediatrix Medical Group in a research report on Friday, February 20th.

Pediatrix Medical Group Stock Performance

Pediatrix Medical Group stock opened at $24.19 on Wednesday. The firm’s 50 day simple moving average is $22.55 and its 200-day simple moving average is $21.71. The company has a market cap of $1.99 billion, a P/E ratio of 11.74 and a beta of 0.69. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.33 and a quick ratio of 1.33. Pediatrix Medical Group has a fifty-two week low of $11.84 and a fifty-two week high of $24.99.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Tuesday, May 5th. The company reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The business had revenue of $476.20 million for the quarter, compared to the consensus estimate of $465.83 million. During the same period last year, the firm posted $0.33 earnings per share. The firm’s quarterly revenue was up 3.9% compared to the same quarter last year. As a group, equities research analysts predict that Pediatrix Medical Group will post 2.1 EPS for the current year.

Insider Buying and Selling

In other Pediatrix Medical Group news, Director Shirley A. Weis sold 36,028 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $23.75, for a total value of $855,665.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 1.80% of the stock is owned by corporate insiders.

Institutional Trading of Pediatrix Medical Group

Several large investors have recently added to or reduced their stakes in MD. Royal Bank of Canada grew its position in Pediatrix Medical Group by 23.8% in the first quarter. Royal Bank of Canada now owns 22,097 shares of the company’s stock worth $320,000 after acquiring an additional 4,247 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Pediatrix Medical Group by 4.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,253 shares of the company’s stock worth $743,000 after acquiring an additional 2,251 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Pediatrix Medical Group by 4.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,506 shares of the company’s stock worth $3,891,000 after acquiring an additional 12,171 shares in the last quarter. Cetera Investment Advisers bought a new stake in Pediatrix Medical Group in the second quarter worth approximately $145,000. Finally, Quantbot Technologies LP bought a new stake in Pediatrix Medical Group in the second quarter worth approximately $99,000. 97.71% of the stock is owned by institutional investors.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.